VIVA
维亚生物科技控股集团
VIVA BIOTECH HOLDINGS
Stock Code: 1873

NEWSLETTER

September-December 2025, Issue 22

Highlights

I . Business Progress

- Viva Biotech Receives Frost & Sullivan's 2025 APAC Technology Innovation Leadership Recognition in the Integrated Intelligent Drug Discovery Industry
- Building the Next Generation of Biologics: Inside the Future of Protein Engineering
- New Technology and New Ideas: Viva Biotech Shared the Practical Experience of AI Drug Development and Production in SAPA-China 2025
- A Forum of Industry, Academia, Research, and Investment: A Profound Discussion on the Development of New Modalities
- Innovation for Live — A Recap of 2025

II . Capital Market Progress

- Viva Biotech Launches an Equity Incentive Plan for Its Core Employees, Granting 8.58 Million Share Options
- Viva Biotech Update Announcement Regarding Equity Matters, VIVA Shanghai Repurchase Obligation Exercise Period Extended to 2028

III. Portfolio Companies' Project Progress

- Ophidion, Inc. and Neuronasal, Inc. Announce Strategic Collaborations to Tackle Parkinson's Disease, Obesity, and Diabetes via Novel CNS Delivery Platform
- Arthrosi Enters into an Acquisition Agreement with Sobi for a Total Transaction Value of up to US$1.5 Billion, following the Completion of $153 Million in Series E Financing
- Apeiron Therapeutics Presents First-in-Human Data from Phase 1 Clinical Trial of GTA182 in MTAP-Deleted Advanced Non-Small Cell Lung Cancer at the ESMO Asia Congress 2025
- Proviva Therapeutics Raises Over $30 Million in Series A+ Financing to Advance First-in-Class PD-1/IL-2 Pro-drug Fusion Protein PTX-912
- AmacaThera Signs Exclusive Global Licensing Agreement with Pacira BioSciences for Up To US$230 Million, Validating Its Tunable Drug Delivery Platform
- Domain Therapeutics Doses First Patients in Phase I / II Trial of DT-7012 Targeting CCR8 in Solid Tumors
- Basking Biosciences Doses First Patients in Part B of Phase 2 Stroke Trial, Unlocks $27.5 Million Financing Tranche
- TJ Biopharma Completed Financing of Nearly RMB 600 million to Accelerate the Commercialization and Globalization of Innovative Drugs

Business Progress

Viva Biotech Receives Frost & Sullivan's 2025 APAC Technology Innovation Leadership Recognition in the Integrated Intelligent Drug Discovery Industry

- September 29, 2025 – Viva Biotech announced today that it has been honored with Frost & Sullivan's 2025 APAC Technology Innovation Leadership recognition in the Integrated Intelligent Drug Discovery industry. As Frost & Sullivan's top honor, the award recognizes outstanding achievements in driving transformative efficiencies in preclinical research and development. It highlights Viva Biotech's consistent leadership in combining artificial intelligence (AI) with laboratory-driven validation to reshape the future of drug discovery, strengthen client partnerships, and deliver scalable innovation in a highly competitive landscape.

Building the Next Generation of Biologics: Inside the Future of Protein Engineering

- Recently, Viva Biotech contributed to the research published in BioSpace, titled "***Building the Next Generation of Biologics: Inside the Future of Protein Engineering***". This article focuses on the molecular complexity encountered by next generation biologics in the early-stage drug discovery, and further elaborates on how this challenge manifests in conventional R&D workflows. Read the full article **here**.

New Technology and New Ideas: Viva Biotech Shared the Practical Experience of AI Drug Development and Production in SAPA-China 2025.

- SAPA-China 2025 Pharmaceutical Industry Conference was held in Suzhou from October 31st to November 1st. Viva Biotech was invited to participate in the exhibition, and Dr. Jianguo Ma, Senior Vice President of Viva Biotech Group, and Dr. Yue Qian, Executive Director of Viva Biotech Shanghai Computational Chemistry and Artificial Intelligence Platform, brought wonderful themes to share at the Conference.
- In the keynote speech "Design of AI-Empowering Peptide Drugs", Dr. Yue Qian systematically introduced the calculation methods of Viva Biotech in the field of peptide drug research and development. She pointed out that the design of polypeptide drugs faces three major challenges: huge chemical space, difficult to accurately describe conformational space and complex structure-activity relationship. In order to solve these problems, Viva Biotech established a proprietary unnatural amino acid library, developed a 3D structural prediction model based on deep learning, and made a comprehensive evaluation with a multi-dimensional scoring system. Focusing on the theme of "API development - China Road from Generic Drugs to Innovative Drugs", Dr. Jianguo Ma reviewed the development context and policy evolution of generic drugs and innovative drugs in China pharmaceutical industry. He pointed out that the introduction of a series of key policies has pushed the research and development of generic drugs and innovative drugs in China into the track of international standardization, especially in the field of Chemistry, Manufacturing, and Controls (CMC).

Business Progress

A Forum of Industry, Academia, Research, and Investment: A Profound Discussion on the Development of New Modalities

- On September 26th, Viva Biotech held an industry salon with the theme of "Breaking Through Traditional Boundaries: Innovation and Application Expansion of New Modalities". Experts from all walks of life in Industry, Academia, Research, and Investment gathered at Viva Biotech to conduct in-depth discussions on technical exchanges and the future development of New Modalities.
- Dr. Derek Ren first introduced the company's development history and strategic layout, and summarized Viva Biotech's four core competitiveness: the world's leading protein and structural biology capabilities (including cryo-EM technology), unique affinity screening system (from ASMS, SPR to DEL), excellent medicinal chemistry capabilities, and drug design platform driven by artificial intelligence. Subsequently, Dr. Yongqiang Shan combed the evolution of drug research and development from three levels of "Molecule-Gene-Regeneration". Dr. Shan believed that no matter what mode, the disease would be solved eventually. Dr. Junqing Cui discussed how pharmacology can keep pace with diversified R&D needs, starting with the topic of "from oncology, autoimmune diseases to the GLP-1 weight-loss drug boom, with the continuous emergence of innovative drugs such as antibodies, PROTACs, peptides, and XDCs." He also introduced the company's integrated pharmacodynamics platform, which encompasses comprehensive services including DMPK research on small molecules, peptides, and macromolecules, immunological testing, and efficacy evaluation of drugs for oncology and autoimmune diseases. Finally, Dr. Xinyu Deng, as the head of Viva Biotech's macromolecule platform, shared innovative drug design ideas and typical cases, starting from the interconversion of drug modalities, such as antibody modification into peptides, peptide integration into antibodies, and antibody peptide conjugation.

Innovation for Live — A Recap of 2025

- Recently, Viva Biotech released a recap of 2025, covering its global business footprint, technical innovation advances, value co-creation efforts, as well as corporate accountability. Read the full article **here**.

Capital Market Progress

Viva Biotech Launches an Equity Incentive Plan for Its Core Employees, Granting 8.58 Million Share Options.

- Viva Biotech announced on December 2, 2025 that, pursuant to the Post-IPO Share Option Scheme adopted on April 14, 2019, the Company granted 8,580,000 share options to eligible participants. The grantees are 44 core employees of the Group's CDMO operations, none of them are Director, chief executive or substantial shareholder of the Company or an associate of any of them. The exercise price of the share options is HK$2.05 per Share. These share options will vest in three tranches: 40% on March 31, 2028, 30% on March 31, 2029, and the remaining 30% on March 31, 2030. The vesting performance targets require the Group's revenue in 2027, 2028 and 2029 financial year to increase by no less than 35%, 55% and 75% respectively compared with that in 2025. Meanwhile, grantees must also meet tier-ed individual performance targets based on comprehensive annual appraisal results.

Viva Biotech Update Announcement Regarding Equity Matters, VIVA Shanghai Repurchase Obligation Exercise Period Extended to 2028

- Viva Biotech announced on January 5, 2026 that it had received an irrevocable declaration letter from each of HLC SPV, Qingdao Hongyi, Daxue Investments, True Light P and Raed Capital Holdings 2 Ltd, reaching a consensus on the extension of the equity Repurchase Obligation in respect of VIVA Shanghai. Pursuant to the Shareholders Agreement, in the event that VIVA Shanghai fails to complete the Qualified IPO or achieve a qualified merger and acquisition transaction on or before December 31, 2026, the investors have a right and shall demand Viva Biotech and the relevant Obligors to repurchase the equity interest held by them.
- This announcement clarifies that the Viva Shanghai Investors have agreed to temporarily suspend the exercise period of the aforesaid repurchase right, with the period extended to December 31, 2028. During the extension period from December 31, 2026 to December 31, 2028, each investor shall not assert their rights relating to the Repurchase Obligation in any manner. There have been no amendments to the Shareholders Agreement and all other terms of the Shareholders Agreement will continue to remain effective, all obligations under the Shareholders Agreement will continue to accrue during such period.
- The Viva Shanghai Investors' decision to extend the period is mainly based on a comprehensive consideration of the prevailing market conditions, the latest business development of VIVA Shanghai, including its business and capital raising plans. This demonstrates the Viva Shanghai Investors' confidence in the business of VIVA Shanghai, as well as their belief that they could continue to realize their investment purpose notwithstanding the temporary suspension of their rights to enforce the Repurchase Obligations.

Portfolio Companies' Project Progress

Ophidion, Inc. and Neuronasal, Inc. Announce Strategic Collaborations to Tackle Parkinson's Disease, Obesity, and Diabetes via Novel CNS Delivery Platform

- Dec. 15, 2025, Ophidion, Inc., invested and incubated by Viva BioInnovator (VBI), a biotechnology company pioneering non-invasive delivery of gene-silencing and large-molecule therapeutics to the brain, and Neuronasal, Inc., a clinical-stage company advancing patented nose-to-brain delivery of therapeutics, announced a strategic partnership to co-develop multiple therapeutic candidates targeting key pathways in Parkinson's disease as well as the treatment of obesity and diabetes.

Arthrosi Enters into an Acquisition Agreement with Sobi for a Total Transaction Value of up to US$1.5 Billion, following the Completion of $153 Million in Series E Financing

- Dec. 13, 2025, Swedish Orphan Biovitrum AB (STO:SOBI) recently announced that it has entered into an acquisition agreement with Arthrosi Therapeutics, Inc., which was invested in and incubated by Viva Biotech Holdings. Under the terms of the agreement, Sobi will pay up to US$1.5 billion in total transaction value, including an upfront payment at closing of US$950 million, subject to customary adjustments, and contingent consideration of up to US$550 million. The transaction is expected to close in the first half of 2026.
- On Oct. 8, Arthrosi announced the closing of its $153 million Series E financing and the company plans to use the proceeds to complete the clinical development of its lead program, pozdeutinurad (AR882), through its replicate Phase 3 REDUCE 1 and REDUCE 2 studies evaluating pozdeutinurad for the treatment of gout and tophaceous gout.

Apeiron Therapeutics Presents First-in-Human Data from Phase 1 Clinical Trial of GTA182 in MTAP-Deleted Advanced Non-Small Cell Lung Cancer at the ESMO Asia Congress 2025

- December 5, 2025, Apeiron Therapeutics, a precision oncology company leveraging structural biology and AI-guided molecular modeling for drug discovery, today presented new clinical data from its ongoing Phase 1 study evaluating GTA182, an oral, brain-penetrant, MTA-cooperative PRMT5 inhibitor, in patients with MTAP-deleted advanced solid tumors, including preliminary antitumor activity in non-small cell lung cancer (NSCLC). These data were presented by Shun Lu, M.D., Ph.D., Professor at Shanghai Chest Hospital and the leading principal investigator on the trial, in a mini-oral session at the ESMO Asia Congress 2025 in Singapore.
- At the ESMO Asia Congress 2025, Apeiron Therapeutics presents first-in-human data from Phase 1 clinical trial of GTA182 in MTAP-deleted advanced non-small cell lung cancer:
  - GTA182 demonstrates favorable safety, dose-proportional pharmacokinetics, robust PRMT5 pathway inhibition, and encouraging early antitumor activity.
  - In MTAP-deleted NSCLC, preliminary results show a 57.1% objective response rate and evidence of intracranial activity.

Portfolio Companies' Project Progress

Proviva Therapeutics Raises Over $30 Million in Series A+ Financing to Advance First-in-Class PD-1/IL-2 Pro-drug Fusion Protein PTX-912

- Dec. 1, 2025, Proviva Therapeutics, Inc., invested and incubated by Viva BioInnovator (VBI), announced the successful completion of its over $30 million Series A+ financing. The round was led by OrbiMed, with participation from renowned investors including
- Hankang Capital, HSG and a well-known global fund. Proceeds will support the global clinical development of the company's lead asset, PTX-912, and advance multiple additional preclinical programs.

AmacaThera Signs Exclusive Global Licensing Agreement with Pacira BioSciences for Up To US$230 Million, Validating Its Tunable Drug Delivery Platform

- Nov. 4, 2025, AmacaThera, invested and incubated by Viva BioInnovator (VBI), a leading developer of next generation hydrogel-based drug delivery solutions that enable precise, tunable, and sustained release to improve a wide range of active therapeutics, announced an exclusive worldwide licensing agreement with Pacira BioSciences, Inc., a leader in non-opioid pain management, for the development and commercialization of AMT-143, an investigational long-acting non-opioid anesthetic for post-operative pain.
- Under the terms of the agreement, AmacaThera will receive US$5 million upfront and up to US$225 million in future development- and sales-based milestone payments and a tiered royalty on future net sales. The companies will collaborate on clinical development, with AmacaThera leading select clinical studies. Pacira will fund clinical development of AMT-143 through commercial launch.

Domain Therapeutics Doses First Patients in Phase I / II Trial of DT-7012 Targeting CCR8 in Solid Tumor

- Oct. 28, 2025, Domain Therapeutics, invested and incubated by Viva BioInnovator (VBI), the GPCR experts harnessing deep receptor biology to develop breakthrough treatments for patients, announced that the first patients have been dosed in its Phase I / II DOMISOL clinical study of DT-7012, a differentiated Treg-depleting anti-CCR8 monoclonal antibody for the treatment of solid tumors.

Basking Biosciences Doses First Patients in Part B of Phase 2 Stroke Trial, Unlocks $27.5 Million Financing Tranche

- Oct. 22, 2025, Basking Biosciences (Basking), invested and incubated by Viva BioInnovator (VBI), a clinical-stage biopharmaceutical company developing the first reversible thrombolytic therapy for acute ischemic stroke (AIS), announced the first patients dosed in Part B of its Phase 2 RAISE trial of BB-031.
- Progression into Part B, supported by encouraging early results from Part A and the recommendation of the Data Safety Monitoring Committee (DSMC), triggered the release of the second $27.5 million tranche of the company's $55 million financing. The new funds will support the execution of Part B of the Phase 2 RAISE trial and a planned Phase 1 study of BB-025.

Portfolio Companies' Project Progress

TJ Biopharma Completed Financing of Nearly RMB 600 million to Accelerate the Commercialization and Globalization of Innovative Drugs

- On September 30, 2025, TJ Biopharma, a full-chain biotechnology company focused on innovative biopharmaceutical discovery, clinical development, production, and collaborative commercialization in the fields of autoimmune diseases, oncology, and metabolic diseases, with investment from Viva Biotech, announced the successful completion of nearly RMB 600 million in its C2 round of financing. This round was led by a fund under CICC Capital, with participation from Yijing Capital, Oriental Fortune Capital, Zhike Fund, Chunling Private, NNFE Fund, and other institutions. Existing shareholders Heda Capital, Tsing Song Capital, Yi Capital, and Qiantang New Area Urban Development also continued to increase their investment.

VIVA

Listing Date
B2019.05.09

Price (2026.1.27)
HKD 2.5

52 WK Range
HKD 0.78 – 3.27

Market Cap (2026.1.27)
HKD 5.325 Billion

Established in 2008, Viva Biotech (01873.HK) provides one-stop services ranging from early-stage Structure-Based Drug R&D to commercial manufacturing to global biopharmaceutical innovators. We offer leading early-stage to late-phase drug discovery expertise by integrating our dedicated team of experts, cutting-edge technology platforms, and state-of-the-art equipment in X-ray crystallization, Cryo-EM, DEL, ASMS, SPR, HDX, AIDD/CADD, and much more. Our business covers all aspects of therapeutic strategies and drug modalities, including small molecules and biologics across the pharma and biotech spectrum. The experienced chemistry team, led by senior medicinal chemists and drug discovery biologists, provides services for drug design, medicinal chemistry (hit to lead and lead optimization), custom synthesis, chemical analysis and purification, kilogram scale-up, peptide synthesis and corresponding bioassays. With our subsidiary, Langhua Pharma, we offer our worldwide pharmaceutical and biotech partners a one-stop integrated CMC (Chemical, Manufacturing, and Control) service from preclinical to commercial manufacturing. Additionally, Viva embedded an equity for service (EFS) model to high potential startups to address unmet medical needs.

As of June 30, 2025, Viva Biotech had cumulatively provided drug R&D and manufacturing services to 2,574 biotech and pharmaceutical clients around the world. We have invested and incubated 93 biotech start-ups in total. In the future, the company will continue to strengthen its technological barriers and improve R&D, production levels, and our service capacity to provide high-quality and diversified services for more drug discovery start-ups, as well as medium and large pharmaceutical enterprises around the world.

Investor & Media Enquiries
Viva Biotech Holdings website: www.vivabiotech.com
For further information, please contact:Tel: +86(0)21-6089 3288
Email: ir@vivabiotech.com